Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay

Biocept Inc BIOC has announced new data from a study assessing its cerebrospinal fluid assay, CNSide.
Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.
The study will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology.
Related: Biocept Collaborates With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients.
An estimated 3-9% of NSCLC diagnosed patients develop leptomeningeal carcinomatosis (LMC), a complication in which cancer spreads to the membranes surrounding the brain and spinal cord.
Huntsman Cancer Institute used Biocept's CNSide assay to detect and analyze tumor cells in the cerebrospinal fluid of 15 patients.
Of the samples analyzed, CNSide detected tumor cells in 100% of samples with LMC, while cytology detected tumor cells in just 40% of the samples.
CNSide also identified actionable biomarkers in tumor cells, which allowed oncologists to make targeted treatment decisions.
The study results suggest that CNSide is more sensitive than cytology.
Price Action: BIOC shares are up 5.16% at $3.72 during the market session on the last check Thursday.